Market Overview

UPDATE: Jefferies Raises PT on WuXi PharmaTech Following Raised 2013 EPS Guidance


In a report published Tuesday, Jefferies analyst David Windley reiterated a Buy rating on WuXi PharmaTech (NYSE: WX), and raised the price target from $24.00 to $28.00.

In the report, Jefferies noted, “Management signaled its forward optimism by raising its guidance mid-point by $0.06-0.07 more than the 2Q13 upside. Headline results for 2Q were well ahead of consensus, and slightly better than us on revenue, GM, and EPS (even ex-FX gains and 1x tax benefits). WX remains one of the more consistent CRO performers. It is also the cheapest of the CROs despite its favorable growth outlook. PT to $28.”

WuXi PharmaTech closed on Monday at $23.76.

Latest Ratings for WX

Oct 2015DowngradesOverweightEqual-Weight
Mar 2015DowngradesBuyNeutral
Nov 2014DowngradesBuyHold

View More Analyst Ratings for WX
View the Latest Analyst Ratings

Posted-In: David Windley JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (WX)

View Comments and Join the Discussion!

Latest Ratings

SIVBMaxim GroupMaintains300.0
VIACMorgan StanleyReinstates42.0
APDBMO CapitalMaintains275.0
OIDeutsche BankMaintains15.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at